Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis

Kotyla, Przemysław; Sliwińska-Kotyla, B; Kucharz, Eugene J.

doi:10.1007/s10067-007-0657-3

Cited by 14 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A double-blind clinical trial using lenercept, a soluble dimeric p55 TNF-IgG fusion protein, illustrated a statistically signifi cant increase in episodes of multiple sclerosis compared with placebo ( 8 ). Another prospective study illustrated decreased conduction velocity on electromyography after 12 months of infl iximab therapy ( 9 ). Several case reports illustrate the development of biopsy-confi rmed aseptic, autoimmune meningitis soon after the initiation of TNF-α inhibitors ( 2 -4 ).…”

Section: Discussionmentioning

confidence: 99%

Rheumatoid Meningitis Associated with Infliximab

Seago¹,

Stroberg²,

Metting³

2016

Baylor University Medical Center Proceedings

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Rheumatoid Meningitis Associated with Infliximab

Seago¹,

Stroberg²,

Metting³

2016

Baylor University Medical Center Proceedings

View full text Add to dashboard Cite

“…All the patients enrolled in that study used infliximab. The study showed that biological agent use affected nerve conduction velocities, though it must not be forgotten that there are effects on nerve conduction in RA itself [15]. We encountered no similar studies on AS in the literature.…”

Section: Discussionmentioning

confidence: 93%

Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis

et al. 2010

View full text Add to dashboard Cite

The objective of this study was to investigate any relationship between peripheral neuropathy and anti-TNF-α therapy used in ankylosing spondylitis (AS). Thirty-nine patients monitored in our clinic with a diagnosis of AS and without neuropathic symptoms were enrolled in the study. Patients were divided into two groups. The first consisted of 21 patients using biological agents for more than one year. The control group was made up of 18 patients of similar age and demographic characteristics receiving non-biological therapy. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were calculated, and sedimentation rate and C-reactive protein (CRP) levels measured. Motor and sensory nerve conduction analysis for the median, tibial, and sural nerves was performed. The nerve conduction results of the biological therapy group were then compared with those of the non-biological therapy group. Thirty-nine patients with a mean age of 37.05 ± 8.1 were enrolled. Patients were divided into two groups, depending on drugs used. The first group (using anti-TNF-α) consisted of 21 patients with a mean age of 42.2 ± 8.8, and the second (the non-biological group) of 18 patients with a mean age of 35.8 ± 7.5. There was no statistically significant difference between the groups in terms of age, sex, drug use, or duration of disease (p = 0.052, p = 0.55, p = 0.33, and p = 0.72, respectively). Sedimentation rate, CRP, and BASDAI scores were statistically significantly higher in the second group (p = 0.04, p = 0.03, and p = 0.009, respectively). No statistically significant difference was determined in any parameters at nerve conduction analysis between the two groups (p > 0.05). There was a positive correlation between sedimentation rate and median sensory conduction velocity (p = 0.02, r = 0.48) and tibial conduction velocity (p = 0.07, r = 0.43). A negative correlation was determined between duration of disease and median distal motor latency (p = 0.22, r = -0.37) and between length of drug use and median sensory conduction velocity (p = 0.02, r = -0.38). There was no significant correlation between other clinical and demographic data and nerve conduction parameters. No effect on nerve conduction of biological agents in AS patients without neurological symptoms was determined. Clinicians should be alert for signs and symptoms, suggesting neuropathy in patients given anti-TNF-α.

show abstract

“…Although our data fail to confirm an absolute association of neurological AEs and these drugs, previous studies have suggested that TNF‐α inhibitors may unmask preclinical neurological disease. A prospective study was conducted by Kotyla et al ., involving 28 patients (26 women and 2 men) with active RA, with normal baseline nerve conduction amplitudes and velocities. Electromyograms after 12 months of infliximab therapy demonstrated increased motoneuronal amplitude in median nerve (4.93 vs. 8.06 mV) and a decrease in conduction velocity in the tibial (50.88 vs. 47.08 m/s) and sural nerves (48.73 vs. 44.93 m/s).…”

Section: Discussionmentioning

confidence: 99%